Developing a patented non-invasive, saliva-based diabetes monitoring test
DiabetOmics, a global medical diagnostics company is developing a patented non-invasive, saliva-based diabetes monitoring test. It is also setting up their global manufacturing facility in the industrial park in Medak, near Hyderabad. DiabetOmics will utilise this facility to commercialise their non-invasive diabetes tests in India and around the world. Ventureast led a $4.1 million investment in DiabetOmics in 2015.
Jupally Krishna Rao, Minister for Industries, Government of Telangana, presided over the foundation stone laying ceremony.
Dr Srinivasa Nagalla, CEO, DiabetOmics, said, “The non-invasive diabetes test is an innovation that could change the approach to the detection and monitoring of diabetes globally, which will improve patient outcomes and provide an opportunity to reduce the economic burden for developing middle and low income countries.”
Venkatadri Bobba, Director-DiabetOmics and General Partner, Ventureast said, “DiabetOmics is definitely going to disrupt the current method of diabetes testing in the world. We are excited that the Indian manufacturing facility will help us commercialise the product in our country and globally. We are optimistic about the patient benefits and economic returns it presents to all of its stakeholders”.
Dr Varaprasad Reddy, Founder Santha Biotech and Chairman Diabetomics India, said, “We are excited that our manufacturing facility is going to be in India keeping in line with the Make-in-India initiative. We feel the innovative non-invasive testing is free of pain and patient friendly. The technology is suited for bringing in low-cost and affordable tests compared to current blood sugar monitoring tests.”
- Advertisement -
Comments are closed.